{"entity":{"id":"nct05923008","kind":"trial","name":"A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of IBI130 in advanced solid tumours, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.","summary":"A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05923008 by Innovent Biologics (Suzhou) Co. Ltd., with 182 participants planned, started 2023-11-14 and due to reach its primary completion in 2024-11-30. Interventions recorded: IBI130.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05923008","url":"https://clinicaltrials.gov/study/NCT05923008"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05923008","phase":"1/2","setting":"A Phase 1/2, Multicenter, Open-label Study of IBI130 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","enrolled":182,"outcomes":[]},"route":"/trials/nct05923008/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}